Profiling immunohistochemical expression of NOTCH1-3, JAGGED1, cMET, and phospho-MAPK in 100 carcinomas of unknown primary

Clinical and Experimental Metastasis

Volumn 29, Issue 6, 2012, Pages 603-614

  Krikelis, Dimitrios ^a   Pentheroudakis, George ^b,c   Goussia, Anna ^b   Siozopoulou, Vassiliki ^b   Bobos, Mattheos ^a   Petrakis, Dimitrios ^b   Stoyianni, Aikaterini ^b   Golfinopoulos, Vassilios ^b,c   Cervantes, Andres ^d   Ciuleanu, Tudor ^e   Fountzilas, George ^a,c   Malamou Mitsi, Vassiliki ^b   Pavlidis, Nicholas ^b,c  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b UNIVERSITY OF IOANNINA   (Greece)

^c Hellenic Cooperative Oncology Group   (Greece)

^d UNIVERSITY OF VALENCIA   (Spain)

^e THE ONCOLOGY INSTITUTE PROF DR ION CHIRICUTA   (Romania)

Author keywords

Cancer of unknown primary; Immunohistochemistry; Jagged; MAPK; MET; Notch

Indexed keywords

JAGGED1; MITOGEN ACTIVATED PROTEIN KINASE; NOTCH1 RECEPTOR; NOTCH2 RECEPTOR; NOTCH3 RECEPTOR; SCATTER FACTOR RECEPTOR;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER OF UNKNOWN PRIMARY SITE; CANCER PROGNOSIS; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERITONEUM METASTASIS; PLEURA METASTASIS; PREDICTIVE VALUE; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SOFT TISSUE METASTASIS; SQUAMOUS CELL CARCINOMA; TISSUE MICROARRAY;

AGED; CALCIUM-BINDING PROTEINS; CARCINOMA; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LINEAR MODELS; MALE; MAP KINASE SIGNALING SYSTEM; MEMBRANE PROTEINS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM METASTASIS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-MET; RECEPTOR, NOTCH1; RECEPTOR, NOTCH2; RECEPTORS, NOTCH;

EID: 84863637373     PISSN: 02620898     EISSN: 15737276     Source Type: Journal    
DOI: 10.1007/s10585-012-9474-4     Document Type: Article

References (37)

1. Golfinopoulos V, Pentheroudakis G, Salanti G, Nearchou AD, Io-annidis JP, Pavlidis N (2009) Comparative survival with diverse chemotherapy regimens for cancer of unknown primary site: multiple-treatments meta-analysis. Cancer Treat Rev 35:570-573
2. Borggrefe T, Oswald F (2009) The Notch signaling pathway: transcriptional regulation at Notch target genes. Cell Mol Life Sci 66:1631-1646
3. Miele L (2006) Notch signaling. Clin Cancer Res 12:1074-1079
4. Miele L, Miao H, Nickoloff BJ (2006) NOTCH signaling as a novel cancer therapeutic target. Curr Cancer Drug Targets 6:313-323
5. Wang Z, Li Y, Kong D, Sarkar FH (2010) The role of Notch signaling pathway in epithelial-mesenchymal transition (EMT) during development and tumor aggressiveness. Curr Drug Targets 11:745-751
6. Wang Z, Li Y, Banerjee S, Sarkar FH (2009) Emerging role of Notch in stem cells and cancer. Cancer Lett 279:8-12
7. McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, Chang F, Lehmann B, Terrian DM, Milella M, Tafuri A, Stivala F, Libra M, Basecke J, Evangelisti C, Martelli AM, Franklin RA (2007) Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta 1773:1263-1284
8. Davis JM, Navolanic PM, Weinstein-Oppenheimer CR, Steelman LS, Hu W, Konopleva M, Blagosklonny MV, McCubrey JA (2003) Raf-1 and Bcl-2 induce distinct and common pathways that contribute to breast cancer drug resistance. Clin Cancer Res 9:1161-1170
9. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF (2003) Met, metastasis, motility and more. Nat Rev Mol Cell Biol 4:915-925
10. Pavlidis N, Briasoulis E, Hainsworth J, Greco FA (2003) Diagnostic and therapeutic management of cancer of an unknown primary. Eur J Cancer 39:1990-2005
11. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM (2005) Reporting recommendations for tumor marker prognostic studies. J Clin Oncol 23:9067-9072
12. Hainsworth JD, Lennington WJ, Greco FA (2000) Overexpres-sion of Her-2 in patients with poorly differentiated carcinoma or poorly differentiated adenocarcinoma of unknown primary site. J Clin Oncol 18:632-635
13. Pavlidis N, Briassoulis E, Bai M, Fountzilas G, Agnantis N (1995) Overexpression of C-myc, Ras and C-erbB-2 oncoproteins in carcinoma of unknown primary origin. Anticancer Res 15: 2563-2567
14. Dova L, Pentheroudakis G, Georgiou I, Malamou-Mitsi V, Var-tholomatos G, Fountzilas G, Kolaitis N, Kitsiou E, Pavlidis N (2007) Global profiling of EGFR gene mutation, amplification, regulation and tissue protein expression in unknown primary carcinomas: to target or not to target? Clin Exp Metastasis 24:79-86
15. Dova L, Pentheroudakis G, Golfinopoulos V, Malamou-Mitsi V, Georgiou I, Vartholomatos G, Ntemou A, Fountzilas G, Pavlidis N (2008) Targeting c-KIT, PDGFR in cancer of unknown primary: a screening study for molecular markers of benefit. J Cancer Res Clin Oncol 134:697-704
16. Briasoulis E, Tsokos M, Fountzilas G, Bafaloukos D, Kosmidis P, Samantas E, Skarlos D, Nicolaides C, Pavlidis N (1998) Bcl2 and p53 protein expression in metastatic carcinoma of unknown primary origin: biological and clinical implications. A Hellenic Cooperative Oncology Group study. Anticancer Res 18:1907-1914
17. Karavasilis V, Malamou-Mitsi V, Briasoulis E, Tsanou E, Kitsou E, Kalofonos H, Fountzilas G, Fotsis T, Pavlidis N (2005) Angiogenesis in cancer of unknown primary: clinicopathological study of CD34, VEGF and TSP-1. BMC Cancer 5:25
18. Hainsworth JD, Spigel DR, Rubin MS, Boccia RV, Fox EP, Firdaus I, Erlander MG, Schnabel C, Greco FA (2010) Treatment of carcinoma of unknown primary site (CUP) directed by molecular profiling diagnosis: a prospective, phase II trial. J Clin Oncol 28
19. Dang TP, Gazdar AF, Virmani AK, Sepetavec T, Hande KR, Minna JD, Roberts JR, Carbone DP (2000) Chromosome 19 translocation, overexpression of Notch3, and human lung cancer. J Natl Cancer Inst 92:1355-1357
20. Haruki N, Kawaguchi KS, Eichenberger S, Massion PP, Olson S, Gonzalez A, Carbone DP, Dang TP (2005) Dominant-negative Notch3 receptor inhibits mitogen-activated protein kinase pathway and the growth of human lung cancers. Cancer Res 65: 3555-3561
21. Radtke F, Wilson A, Mancini SJ, MacDonald HR (2004) Notch regulation of lymphocyte development and function. Nat Immunol 5:247-253
22. Harrison H, Farnie G, Howell SJ, Rock RE, Stylianou S, Brennan KR, Bundred NJ, Clarke RB (2010) Regulation of breast cancer stem cell activity by signaling through the Notch4 receptor. Cancer Res 70:709-718
23. Grugan KD, Miller CG, Yao Y, Michaylira CZ, Ohashi S, Klein-Szanto AJ, Diehl JA, Herlyn M, Han M, Nakagawa H, Rustgi AK (2010) Fibroblast-secreted hepatocyte growth factor plays a functional role in esophageal squamous cell carcinoma invasion. Proc Natl Acad Sci USA 107:11026-11031
24. Seiwert TY, Jagadeeswaran R, Faoro L, Janamanchi V, Nallasura V, El Dinali M, Yala S, Kanteti R, Cohen EE, Lingen MW, Martin L, Krishnaswamy S, Klein-Szanto A, Christensen JG, Vokes EE, Salgia R (2009) The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res 69:3021-3031
25. Kim CH, Kim J, Kahng H, Choi EC (2007) Change of E-cadherin by hepatocyte growth factor and effects on the prognosis of hypopharyngeal carcinoma. Ann Surg Oncol 14:1565-1574
26. Yu J, Shi R, Zhang D, Wang E, Qiu X (2011) Expression of integrin-linked kinase in lung squamous cell carcinoma and adenocarcinoma: correlation with E-cadherin expression, tumor microvessel density and clinical outcome. Virchows Arch 458: 99-107
27. Stoyianni A, Goussia A, Pentheroudakis G, Siozopoulou V, Io-achim E, Krikelis D, Golfinopoulos V, Cervantes A, Bobos M, Fotsis T, Bellou S, Fountzilas G, Malamou-Mitsi V, Pavlidis N (2012) Immunohistochemical study of the epithelial-mesenchy-mal transition phenotype in cancer of unknown primary: incidence, correlations and prognostic utility. Anticancer Res
28. Hu YC, Lam KY, Law S, Wong J, Srivastava G (2001) Profiling of differentially expressed cancer-related genes in esophageal squamous cell carcinoma (ESCC) using human cancer cDNA arrays: overexpression of oncogene MET correlates with tumor differentiation in ESCC. Clin Cancer Res 7:3519-3525
29. Crosswell HE, Dasgupta A, Alvarado CS, Watt T, Christensen JG, De P, Durden DL, Findley HW (2009) PHA665752, a small-molecule inhibitor of c-Met, inhibits hepatocyte growth factor-stimulated migration and proliferation of c-Met-positive neuro-blastoma cells. BMC Cancer 9:411
30. Todaro M, Iovino F, Eterno V, Cammareri P, Gambara G, Espina V, Gulotta G, Dieli F, Giordano S, De Maria R, Stassi G (2010) Tumorigenic and metastatic activity of human thyroid cancer stem cells. Cancer Res 70:8874-8885
31. Stella GM, Benvenuti S, Gramaglia D, Scarpa A, Tomezzoli A, Cassoni P, Senetta R, Venesio T, Pozzi E, Bardelli A, Comoglio PM (2011) MET mutations in cancers of unknown primary origin (CUPs). Hum Mutat 32:44-50
32. Radtke F, Raj K (2003) The role of Notch in tumorigenesis: oncogene or tumour suppressor? Nat Rev Cancer 3:756-767
33. Sundaram MV (2005) The love-hate relationship between Ras and Notch. Genes Dev 19:1825-1839
34. Klotz R, Zeimet AG, Reimer D, Muller-Holzner E, Chamson M, Marth C (2008) Activated p38-MAPK and gemcitabine sensitivity in recurrent ovarian cancer. Anticancer Res 28:2975-2980
35. Inno A, Salvatore MD, Cenci T, Martini M, Orlandi A, Strippoli A, Ferrara AM, Bagala C, Cassano A, Larocca LM, Barone C (2011) Is there a role for IGF1R and c-MET pathways in resistance to cetuximab in metastatic colorectal cancer? Clin Colo-rectal Cancer 10:325-332
36. Gu F, Ma Y, Zhang Z, Zhao J, Kobayashi H, Zhang L, Fu L (2010) Expression of Stat3 and Notch1 is associated with cis-platin resistance in head and neck squamous cell carcinoma. Oncol Rep 23:671-676
37. Rudiger T, Hofler H, Kreipe HH, Nizze H, Pfeifer U, Stein H, Dallenbach FE, Fischer HP, Mengel M, von Wasielewski R, Muller-Hermelink HK (2002) Quality assurance in immunohis-tochemistry: results of an interlaboratory trial involving 172 pathologists. Am J Surg Pathol 26:873-882